OS Therapies Inc (NYSE:OSTX – Get Free Report) major shareholder Shalom Auerbach sold 100,000 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the completion of the sale, the insider now owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. This represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shalom Auerbach also recently made the following trade(s):
- On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The stock was sold at an average price of $6.74, for a total value of $112,692.80.
OS Therapies Trading Down 11.7 %
Shares of NYSE OSTX traded down $0.26 during mid-day trading on Tuesday, reaching $1.97. 1,001,666 shares of the company were exchanged, compared to its average volume of 2,153,116. OS Therapies Inc has a 1 year low of $1.58 and a 1 year high of $7.00. The firm has a 50-day moving average of $3.40 and a 200 day moving average of $3.16.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on OSTX
Institutional Investors Weigh In On OS Therapies
An institutional investor recently raised its position in OS Therapies stock. CM Management LLC increased its stake in shares of OS Therapies Inc (NYSE:OSTX – Free Report) by 120.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.
OS Therapies Company Profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
See Also
- Five stocks we like better than OS Therapies
- Profitably Trade Stocks at 52-Week Highs
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What is a Low P/E Ratio and What Does it Tell Investors?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.